The Hidden Immune Signal Accelerating Aging & the Beta Glucan That Fixes It Bob Rountree and Chris

Chris Damo shares his personal protocol: when preparing for international travel, he increases his dose from 500 mg to 1–1.5 g daily, starting about two weeks before departure. He notes that high doses have been used in the literature without issues. Bob Rountree agrees that for people with higher needs—like teachers constantly exposed to childhood illnesses, or those with suppressed immunity—higher doses are appropriate. This approach leverages the concept of immune training: the longer and more consistently the immune system is exposed to beta-glucan, the more robust the response. It's not an acute remedy but a preventive strategy.

Bob Rountree cites published placebo-controlled studies in nursing homes where one group received one capsule of beta-glucan daily for a few weeks before the flu shot. The beta-glucan group showed significantly higher antibody responses. This addresses a major clinical problem: the elderly often fail to mount protective immunity after vaccination, leaving them vulnerable. Bob connects this to the broader issue of immunosenescence, where immune cells become both less responsive and more inflammatory (SASP phenotype). By restoring immune competence, beta-glucan helps bridge the gap. This protocol is simple, low-cost, and could be implemented widely.

Bob Rountree expresses frustration that oncologists often ignore immune status after chemotherapy, accepting prolonged lymphopenia as inevitable. He argues that beta-glucan, with its extensive cancer trial data, should be a standard supportive therapy. In Asia, injectable mushroom beta-glucans are already used for this purpose. For patients who are severely immunosuppressed, higher doses may be needed to jumpstart immune function. Bob also mentions that beta-glucan can be combined with foundational nutrients like vitamins A, B, C, D, zinc, and quercetin for synergistic support. This protocol is for secondary prevention—restoring immune competence after iatrogenic injury.

Bob Rountree calls this the 'alphabet approach'—ABCD zinc and quercetin. He considers these foundational, with beta-glucan as the centerpiece for immune resilience. Chris Damo adds that he also includes probiotics or fermented foods and sometimes nasal xylitol for mucosal defense. This stack is not just for acute illness but for maintaining immune competence in a toxic world. Bob notes that for patients with higher needs—like teachers constantly exposed to childhood illnesses—this combination can be a game-changer. The stack is flexible and can be adjusted based on individual circumstances.

Bob Rountree explains that innate immune cells were thought to have a hardwired, unchanging response. However, new evidence shows that exposure to beta-glucan can alter the methylation patterns of these cells, turning genes on or off so that the next time the immune system encounters a pathogen, it responds more quickly. This means that the longer a person takes yeast beta-glucan, the more primed their innate immune system becomes. This concept of 'immune training' is gaining traction and provides a mechanistic basis for using beta-glucan as a long-term adaptogen rather than an acute remedy. Bob contrasts this with the old debate about cycling echinacea, suggesting that beta-glucan may not need to be cycled because its benefits build over time.

Bob Rountree uses the analogy of a sleeping immune cell with its 'gun in the holster.' When beta-glucan docks onto the receptor, it's a wake-up call: the cell takes the gun out but does not start shooting. Full-blown inflammation requires additional signals—inflammatory cytokines, damage-associated molecular patterns (DAMPs). This multi-step activation means beta-glucan does not willy-nilly turn up the volume; it restores competent surveillance. This is why beta-glucan is not contraindicated in autoimmunity; autoimmunity is a dysregulated response, not a simple overactivity. Beta-glucan helps the immune system distinguish self from non-self more effectively, supporting tolerance.

Chris Damo highlights that clinical trials span lung, breast, gastric cancers, and neuroblastoma. Benefits include improved immune cell counts, better quality of life, and enhanced response to conventional treatment. Bob Rountree adds that in Asia, injectable forms of mushroom beta-glucans are a standard part of oncology, used to bolster immune resilience during chemotherapy. The mechanism involves broad-based immune modulation—enhancing natural killer cell activity, phagocytosis, and possibly reducing chemotherapy-induced immunosuppression. The fact that a single molecule shows efficacy across such diverse cancer types suggests a fundamental immune-restorative property. Bob laments that Western oncologists often ignore immune status, waiting for infections to occur rather than proactively supporting the immune system.

Chris Damo describes the study design: participants were selected if their Dunedin pace of aging was average or worse (aging faster biologically than chronologically). They received 500 mg/day of the BWH Labs beta-glucan for three months. The study is completed and data are being analyzed by True Diagnostic. Results will be presented by colleague Jill Carneahan at the A4M conference in December. The team is optimistic given the wealth of existing evidence on beta-glucan's immune-modulating and anti-inflammatory effects. They also plan to publish the results. This study could provide a new tool for clinicians aiming to address immunosenescence and inflammaging, two key hallmarks of aging.

Chris Damo explains that beta-glucan increases Lactobacillus and Bifidobacterium species, leading to higher short-chain fatty acid production and enhanced gut barrier integrity. This, in turn, influences the gut-brain axis, potentially reducing cortisol and improving mood states. A systematic review published earlier this year found that beta-glucan supplementation improved mood and fatigue in humans. Chris suggests that the gut may be the farthest upstream mechanism, with downstream effects on HPA axis regulation. Bob adds that Saccharomyces cerevisiae (the source of yeast beta-glucan) shares beneficial gut effects with Saccharomyces boulardii, including secretory IgA production. This positions beta-glucan as a multi-target intervention: directly priming immune cells while also fostering a healthy gut ecosystem that supports immune tolerance and stress resilience.

Chris Damo details the work of Dr. Vaclav Vetvicka at the University of Louisville, who has published over 100 beta-glucan papers. In multiple head-to-head studies, he tested commercially available beta-glucan products for immune parameters like phagocytosis and IL-2 production. Consistently, the BWH Labs product (using Glucan 300 raw material, 85% pure) showed the highest activity. In one study titled with 'silver bullet,' it achieved the same phagocytosis at 1/8 the dose of other products. Bob Rountree explains that supplement companies often choose lower purity to hit a price point, but this results in products that require many capsules to reach a therapeutic dose—or are simply ineffective. The Glucan 300 raw material is as pure as orally available beta-glucan gets, short of injectable pharmaceutical grades. This evidence allows clinicians to prescribe with confidence, knowing the exact dose needed for clinical effect.